Global contract research organization (CRO) Frontage Laboratories has entered into a deal to acquire Quintara Discovery, a drug discovery and development specialist based in the San Francisco Bay Area.
 
Established in 2013, Quintara provides in vitro ADME profiling, bioanalytical services, and dedicated assay development and compound screening.
 
“Quintara has an exceptional discovery and development platform that it has leveraged to build a strong reputation with its clients,” said According Song Li, founder, chairman and CEO of Frontage. “Following the addition of the Quintara team’s significant expertise in the areas of discovery and ADME profiling, Frontage will speed up its expansion in drug discovery services. We also expect that Quintara’s location in the San Francisco Bay Area will facilitate the growth of our business on the west coast.”
 
Wentao Zhang, founder and president, Quintara, said, “Frontage has clearly emerged as an extremely strong and highly-regarded CRO partner in the drug development process and we are very enthusiastic about the new opportunities that this transaction will bring to both the Quintara team and our clients. Quintara’s proven discovery platform will complement the wide variety of high-caliber pre-clinical services offered by Frontage Labs, enabling us to provide more integrated pre-clinical services to our clients.”
 
The transaction is expected to close in the third quarter of 2021.
 
Frontage Laboratories provides product development services from drug discovery to late phase clinical process. Services include drug metabolism and pharmacokinetics, analytical testing and formulation development, preclinical and clinical trial material manufacturing, bioanalysis, preclinical safety and toxicology assessment and early phase clinical studies.